A 35-year-old female presents to the ophthalmology clinic 3 days after a lime (calcium hydroxide) burn to the right eye sustained during construction work. She reports persistent pain, photophobia, and blurred vision. On examination, the cornea shows a hazy, scarred appearance with loss of epithelial detail; the conjunctiva is pale and ischemic in the interpalpebral zone; and the anterior chamber is shallow with fibrin deposition. Intraocular pressure is 28 mmHg. What is the most appropriate next step in management?

Explanation

## Post-Acute Management of Alkali Chemical Eye Injury **Key Point:** After the acute irrigation phase, management shifts to preventing secondary complications (scarring, symblepharon, glaucoma, vascularization) and promoting epithelial healing through aggressive medical therapy. ### Classification of Chemical Injuries (Roper Hall) | Grade | Cornea | Conjunctiva | Prognosis | |-------|--------|------------|----------| | **I** | Epithelial defect only | Hyperemia, no blanching | Excellent; heals in days | | **II** | Corneal haze, anterior stroma involved | Blanching in <50% of limbal area | Good; may have mild scarring | | **III** | Corneal opacity obscures iris details | Blanching in 50–99% of limbal area | Guarded; significant scarring likely | | **IV** | Cornea opaque, iris/pupil not visible | Total limbal blanching (100%) | Poor; high risk of blindness, symblepharon, glaucoma | **High-Yield:** This case describes **Grade III–IV injury** (hazy cornea, pale ischemic conjunctiva, anterior chamber involvement). The prognosis is guarded to poor, and aggressive medical management is essential. ### Pathophysiology of Post-Acute Phase 1. **Ongoing inflammation:** Cytokine release, neutrophil infiltration 2. **Corneal scarring:** Myofibroblast activation, collagen remodeling 3. **Conjunctival ischemia:** Limbal stem cell damage → symblepharon, trichiasis 4. **Secondary glaucoma:** Angle damage, inflammation, posterior synechiae 5. **Vascularization:** Neovascularization of cornea (poor prognostic sign) ### Comprehensive Post-Acute Management ```mermaid flowchart TD A[Post-acute alkali burn Day 3+]:::outcome --> B[Assess severity by Roper Hall grade]:::decision B -->|Grade I-II| C[Topical therapy only]:::action B -->|Grade III-IV| D[Systemic + topical therapy]:::action D --> E[Systemic corticosteroids<br/>Oral prednisolone 1 mg/kg/day]:::action D --> F[Topical therapy:<br/>Antibiotics, cycloplegic,<br/>lubricants, ascorbic acid]:::action E --> G[Taper over 4-6 weeks]:::action F --> H[Monitor IOP, epithelialization,<br/>scarring, symblepharon]:::action H --> I{Secondary glaucoma?}:::decision I -->|Yes| J[Add IOP-lowering agents<br/>Beta-blocker, CAI, or PGA]:::action I -->|No| K[Continue medical therapy]:::action J --> L[Consider surgical intervention<br/>if refractory]:::action ``` ### Detailed Medical Regimen | Component | Agent | Dosing | Rationale | |-----------|-------|--------|----------| | **Systemic corticosteroids** | Prednisolone | 1 mg/kg/day PO, taper over 4–6 weeks | Suppress inflammation, reduce scarring, prevent symblepharon | | **Topical antibiotic** | Moxifloxacin or ciprofloxacin | 4 times daily | Prevent bacterial superinfection | | **Cycloplegic** | Cyclopentolate 1% | 3–4 times daily | Reduce ciliary spasm pain; prevent posterior synechiae | | **Lubricant** | Preservative-free artificial tears | Frequent (hourly) | Promote epithelial healing, reduce friction | | **Antioxidant** | Ascorbic acid (vitamin C) | 500 mg PO 4× daily + topical 10% drops | Scavenge free radicals; reduce collagen cross-linking and scarring | | **IOP management** | Beta-blocker (timolol) or CAI (acetazolamide) | As needed | Control secondary glaucoma; avoid PGA initially (may increase inflammation) | | **Topical NSAIDs** | ~~Diclofenac~~ | Avoid | Risk of corneal melting in severe burns | **Clinical Pearl:** Ascorbic acid is a high-yield agent in alkali burns — it reduces the extent of corneal scarring and vascularization by inhibiting collagen cross-linking and suppressing inflammatory mediators. **Warning:** ~~Do not use topical NSAIDs in severe alkali burns~~ — they increase the risk of corneal melting and perforation. Systemic corticosteroids are the anti-inflammatory of choice. ### Long-Term Complications to Monitor 1. **Symblepharon:** Adhesion between conjunctiva and lid; prevent with lubricants and lysis if forming 2. **Trichiasis:** Misdirected eyelashes; may require electrolysis or cryotherapy 3. **Corneal scarring and vascularization:** May require corneal transplantation (but only after 6–12 months of quiescence) 4. **Secondary glaucoma:** From angle damage or inflammation; manage medically or surgically 5. **Entropion/ectropion:** Lid contracture; may require surgical correction **High-Yield:** Corneal transplantation is NOT indicated acutely or in the early post-acute phase. Wait 6–12 months for inflammation to settle and graft bed to stabilize. Early grafting has poor outcomes due to ongoing inflammation and neovascularization. [cite:Khurana Comprehensive Ophthalmology 6e Ch 6, Yanoff & Duker Ophthalmology 5e Ch 4, Roper Hall Classification]